BioInvent International receives a milestone payment from Bayer/Hope Medicine following clinical progression of an out-licensed antibody.
BioInvent receives EUR 500,000 following the enrollment of the first patient in a Phase 2 trial of HMI-115 for the treatment of endometriosis in pre-menopausal women. HMI-115 is an anti-prolactin receptor antibody discovered using BioInvent’s n-CoDeR phage display antibody technology. Originally licensed to Bayer Healthcare as part of a multi-product antibody deal in 2008, Bayer assigned the product license to Shanghai-headquartered Hope Medicine in April 2019. In addition to the Phase 2 trial in endometriosis, Hope Medicine has also received FDA approval of a second IND application for the evaluation of HMI-115 in androgen alopecia.
Six of BioInvent’s out-licensed therapeutic product candidates are in clinical development
Several therapeutic antibodies discovered using BioInvent’s n-CoDeR and F.I.R.S.T screening platform are in development by BioInvent’s collaborators, which entitles BioInvent to significant development milestone payments as well as royalties on potential future sales, the company states. Currently, six of BioInvent’s out-licensed therapeutic product candidates are in clinical development.
Photo of Martin Welschof, CEO, BioInvent: Nille Leander